

VRL/SEC/BSE

June 3rd, 2014

Dept. of Corporate Services
The Stock Exchange, Mumbai
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai

Sub. : VMRC Drug VRP008 To Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has received another patent grant for a novel antibiotic product VRP008 consisting of a carbapenem and a novel aminoglycoside (NCE entity) from EPO. Pioneering into antimicrobial resistance research, VMRC is engaged in research for this product from the past 8 years.

The product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients where the risk of adverse events is high and very low amount of doses are required. It is expected to capture a wide range of market sector which is upheaval with antibiotics for wide indications.

Currently, at least 25,000 people die each year in the European Union from infections due to ESKAPE pathogens which are multi-drug-resistant organisms. The economic impact is estimated at € 1.5 billion per year. Infections caused by these antibiotic-resistant bacteria resulted in approximately 2.5 million extra hospital days annually in Europe.

VMRC recognized the compounding problem of anti-microbial resistance more than 10 years ago, since then the team of Venus is working dedicatedly to provide effective and affordable solution to this problem. Its success in achieving this target is evident from the number of patents it has received from all over the globe for its novel antibiotic entities such as Elores, Potentox, Vancoplus and VRP008 (the research code for this AAE). There is hardly any research going on in this direction and once the product is launched, it will be one of the best solution for ICU infections.

Product is developed by following the stringent international guidelines defined for developing a new drug and has undergone for pre-clinical studies such as Acute Toxicity, Sub Acute toxicity, Intravenous, para venous toxicities as per OECD guidelines, Efficacy

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase-I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH



and Safety studies established through a series of microbiological studies carried out as per CLSI guidelines. Apart from these, stringent stability studies on all four zone conditions including reconstitution stability have been carried out.

In 2009, the global anti-infectives market generated revenues of \$79.12bn for 12 months to second-quarter, 2009. Over this period, the systemic antibacterial market accounted for 46.9% of this market segment reaching \$37.14bn in revenues. The total worldwide revenues for the systemic antibacterials drugs for 12 months to the Q2 were \$37.14bn. Overall growth for the forecast period from 2009 to 2024 is estimated to be 6.76% (CAGR) rising to a figure of \$99.13bn.

Besides this, Venus has also received EU patent for its novel product Elores, Potentox, Vancoplus and Achnil.

Yours faithfully,
for VENUS REMEDIES LIMITED.

Ramanjit
Ramanjit Kaur
Deputy Manager
Corporate Communication



VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase-I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajra EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH